Arrinex

The American company Arrinex is founded in 2013 and began to use actively Clarifix developed by it the device of cryoablation at the end of 2017. Originally, in 2016, Arrinex got approval of regulatory bodies on use of Clarifix technology only for "elimination of undesirable fabrics at surgery", but in a year the company provided data of clinical trial which allowed to use Clarifix for treatment of chronic rhinitis (chronic cold) at adult patients. The headquarters of the company is located to Menlo Park, the State of California.

History

2019: Stryker purchased Arrinex

At the end of February, 2019 Stryker Corporation announced acquisition of Arrinex company and its Clarifix technology for treatment of vasomotorial rhinitis. Cryoablation of Clarifix allows to delete fabric which became a target of allergic triggers or ceased to respond to normal regulation after excess use of vasoconstrictive drops for a nose.

Clarifix system

Acquisition of Arrinex became the next stage of development of LOR-division Stryker which began to extend actively in 2018 thanks to purchase of Entellus company. The transaction allowed Stryker purchase a portfolio of minimum invasive methods of treatment of LOR-pathology, such as balloon XprESS system and the absorbing nasal implant of Latera. Expansion of a portfolio of tools allowed LOR-division of the company to create own group on sales and eventually to purchase Arrinex.

The transaction will allow Stryker company not only to expand a portfolio of offers for treatment of LOR-pathology, but also to come to earlier unavailable segment of the market. Stryker does not own tools for treatment of chronic rhinitis (chronic cold) therefore new acquisition is intended to provide to the company additional inflow of income without the competition to the existing products.^[1]

Notes